{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:33Z","timestamp":1790351673938,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ceftolozane\/tazobactam (C\/T) is approved in 70 countries, including the United States, for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens. C\/T is of particular importance as an agent for the treatment of multidrug-resistant (MDR) <jats:italic>Pseudomonas aeruginosa<\/jats:italic> infections. The current study summarizes 2018\u20132019 data from the United States on lower respiratory tract isolates of Gram-negative bacilli from the SMART global surveillance program. The CLSI reference broth microdilution method was used to determine in vitro susceptibility of C\/T and comparators against isolates of <jats:italic>P. aeruginosa<\/jats:italic> and Enterobacterales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>C\/T inhibited 96.0% of <jats:italic>P. aeruginosa<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u20091237) at its susceptible MIC breakpoint (\u22644\u2009\u03bcg\/ml), including &gt;\u200985% of meropenem-nonsusceptible and piperacillin\/tazobactam (P\/T)-nonsusceptible isolates and 76.2% of MDR isolates. Comparator agents demonstrated lower activity than C\/T against <jats:italic>P. aeruginosa<\/jats:italic>: meropenem (74.8% susceptible), cefepime (79.2%), ceftazidime (78.5%), P\/T (74.4%), and levofloxacin (63.1%). C\/T was equally active against ICU (96.0% susceptible) and non-ICU (96.7%) isolates of <jats:italic>P. aeruginosa<\/jats:italic>. C\/T inhibited 91.8% of Enterobacterales (<jats:italic>n<\/jats:italic>\u2009=\u20091938) at its susceptible MIC breakpoint (\u22642\u2009\u03bcg\/ml); 89.5% of isolates were susceptible to cefepime and 88.0% susceptible to P\/T. 67.1 and 86.5% of extended-spectrum \u03b2-lactamase (ESBL) screen-positive isolates of <jats:italic>Klebsiella pneumoniae<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200985) and <jats:italic>Escherichia coli<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200974) and 49.6% of MDR Enterobacterales were susceptible to C\/T. C\/T was equally active against ICU (91.3% susceptible) and non-ICU (92.6%) Enterobacterales isolates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Data from the current study support the use of C\/T as an important treatment option for lower respiratory tract infections including those caused by MDR <jats:italic>P. aeruginosa<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-021-02135-z","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T08:02:32Z","timestamp":1615017752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections \u2013 SMART United States 2018\u20132019"],"prefix":"10.1186","volume":"21","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle H.","family":"Lob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"2135_CR1","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/jac\/dkz149","volume":"74","author":"O de la Rosa JM","year":"2019","unstructured":"de la Rosa JM O, Nordmann P, Poirel L. ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74:1934\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2135_CR2","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013111.","journal-title":"Clin Infect Dis"},{"key":"2135_CR3","doi-asserted-by":"publisher","first-page":"e00533","DOI":"10.1128\/AAC.00533-18","volume":"62","author":"S Schmidt-Malan","year":"2018","unstructured":"Schmidt-Malan S, Mishra AJ, Mushtaq A, Brinkman CL, Patel R. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2018;62:e00533\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR4","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","volume":"96","author":"HS Sader","year":"2020","unstructured":"Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). Diagn Microbiol Infect Dis. 2020;96:114833.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2135_CR5","doi-asserted-by":"publisher","first-page":"114925","DOI":"10.1016\/j.diagmicrobio.2019.114925","volume":"96","author":"JA Karlowsky","year":"2020","unstructured":"Karlowsky JA, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis. 2020;96:114925.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2135_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jgar.2019.10.009","volume":"21","author":"D Shortridge","year":"2020","unstructured":"Shortridge D, Pfaller MA, Streit JM, Flamm RK. Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme. J Glob Antimicrob Resist. 2020;21:60\u20134.","journal-title":"J Glob Antimicrob Resist"},{"key":"2135_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","volume":"43","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"2135_CR8","doi-asserted-by":"publisher","first-page":"e02125","DOI":"10.1128\/AAC.00313-18","volume":"62","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2018;62:e02125\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR9","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkx136","volume":"72","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, et al. Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;72:2278\u201389.","journal-title":"J Antimicrob Chemother"},{"key":"2135_CR10","unstructured":"ZERBAXA (ceftolozane\/tazobactam) for injection, for intravenous use. Package insert. Merck sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2019."},{"key":"2135_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","volume":"71","author":"JM Pogue","year":"2020","unstructured":"Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, et al. Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71:304\u201310.","journal-title":"Clin Infect Dis"},{"key":"2135_CR12","first-page":"e02252","volume":"61","author":"HS Sader","year":"2017","unstructured":"Sader HS, Huband MD, Castanheira M, Flamm RK. Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. Antimicrob Agents Chemother. 2017;61:e02252\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","volume":"15","author":"SH Lob","year":"2018","unstructured":"Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of imipenem\/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. J Glob Antimicrob Resist. 2018;15:12\u20139.","journal-title":"J Glob Antimicrob Resist"},{"key":"2135_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2017.06.009","volume":"89","author":"TD Trinh","year":"2017","unstructured":"Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: prevalence and risk factors. Diagn Microbiol Infect Dis. 2017;89:61\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2135_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/cid\/cix034","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Rodriguez-Ba\u0148o J. The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections. Clin Infect Dis. 2017;64:972\u201380.","journal-title":"Clin Infect Dis"},{"key":"2135_CR16","doi-asserted-by":"publisher","unstructured":"Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, et al. Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II study). Open Forum Infect Dis. 2020. https:\/\/doi.org\/10.1093\/ofid\/ofaa139.","DOI":"10.1093\/ofid\/ofaa139"},{"key":"2135_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/jac\/dkw374","volume":"72","author":"MW Popejoy","year":"2017","unstructured":"Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials. J Antimicrob Chemother. 2017;72:268\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"2135_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/cid\/ciz173","volume":"69","author":"PD Tamma","year":"2019","unstructured":"Tamma PD, Doi Y, Bonomo RA, et al. A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis. 2019;69:1446\u201355.","journal-title":"Clin Infect Dis"},{"key":"2135_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby GA. AmpC \u03b2-Lactamases. Clin Microbiol Rev. 2009;22:161\u201382.","journal-title":"Clin Microbiol Rev"},{"key":"2135_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, Chung P, Adam H, et al. Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74:31\u201351.","journal-title":"Drugs"},{"key":"2135_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","volume":"70","author":"C Bebrone","year":"2010","unstructured":"Bebrone C, Lassaux P, Vercheval L, Sohier J, Jehaes A, Sauvage E, Galleni M. Current challenges in antimicrobial chemotherapy: focus on beta-lactamase inhibition. Drugs. 2010;70:651\u201379.","journal-title":"Drugs"},{"key":"2135_CR22","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1128\/AAC.03681-14","volume":"58","author":"M Castanheira","year":"2014","unstructured":"Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven \u03b2-lactam resistance mechanisms among contemporary ceftazidime-non-susceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014;58:6844\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR23","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.01410-08","volume":"53","author":"J-M Rodr\u00edguez-Mart\u00ednez","year":"2009","unstructured":"Rodr\u00edguez-Mart\u00ednez J-M, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1766\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR24","doi-asserted-by":"publisher","unstructured":"Arca-Su\u00e1rez J, V\u00e1zquez-Ucha JC, Fraile-Ribot PA, Lence E, Cabot G, Mart\u00ednez-Guiti\u00e1n M, Lasarte-Monterrubio C, et al. Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane\/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection. J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa291.","DOI":"10.1093\/jac\/dkaa291"},{"key":"2135_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X, Peria\u00f1ez L, Mart\u00edn-Pena ML, Juan C, et al. Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73:658\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"2135_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1128\/AAC.02379-15","volume":"60","author":"KM Kazmierczak","year":"2016","unstructured":"Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:1067\u201378.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/cix893","volume":"66","author":"RA Bonomo","year":"2018","unstructured":"Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-producing organisms: a global scourge. Clinical infectious diseases. 2018;66:1290\u20137.","journal-title":"Clinical infectious diseases"},{"key":"2135_CR28","doi-asserted-by":"publisher","first-page":"e00102","DOI":"10.1128\/CMR.00102-19","volume":"33","author":"JDD Pitout","year":"2019","unstructured":"Pitout JDD, Peirano G, Kock MM, Strydom K-A, Matsumura Y. The global ascendency of OXA-48-type Carbapenemases. Clin Microbiol Rev. 2019;33:e00102\u201319.","journal-title":"Clin Microbiol Rev"},{"key":"2135_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D van Duin","year":"2017","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8:460\u20139.","journal-title":"Virulence."},{"key":"2135_CR30","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64:e00397\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"2135_CR31","first-page":"1803","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, et al. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803\u201314.","journal-title":"Clin Infect Dis"},{"key":"2135_CR32","doi-asserted-by":"publisher","unstructured":"Huh K, Chung DR, Ha YE, Ko J-H, Kim S-H, Kim M-J, et al. Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. Clin Infect Dis 2020; doi\/https:\/\/doi.org\/10.1093\/cid\/ciaa084\/5717239.","DOI":"10.1093\/cid\/ciaa084\/5717239"},{"key":"2135_CR33","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 2020. 30th edition, M100. Clinical and laboratory standards institute, Wayne, PA, USA."},{"key":"2135_CR34","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2018. 11th edition, M07-A11. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA, USA."}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-021-02135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12866-021-02135-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-021-02135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T08:02:47Z","timestamp":1615017767000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-021-02135-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1186\/s12866-021-02135-z","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and informed consent was not required because all isolates received into the study followed multiple subcultures and were completely de-identified. The secondary research use of de-identified isolates is considered exempt research according to the Regulations for the Protection of Human Subjects in Research of the U.S. Department of Health and Human Services, Office for Human Research Protections (45 CFR 46).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHL and DFS work for IHMA, which receives funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA for the SMART surveillance program. JAK is a consultant to IHMA, and an employee of the University of Manitoba and Shared Health Manitoba. KY and MRM are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and own stock and options in Merck & Co., Inc., Kenilworth, NJ, USA. The IHMA authors do not have personal financial interests in the sponsor of this manuscript (Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}